Why Moderna Shares Slipped Today
Shares of Moderna (NASDAQ: MRNA) were sliding 4.5% lower as of 3:39 p.m. EDT on Thursday after falling as much as 9% earlier in the day. The decline came after STAT News reported the company's planned late-stage study of COVID-19 vaccine candidate mRNA-1273 could be delayed.
How bad is the latest news for Moderna? It doesn't appear to be anything for investors to be overly concerned about.
Moderna stated last month that it expected to begin a phase 3 study of mRNA-1273 in July. The biotech is making changes to the trial plan that will push back the anticipated start date, according to the STAT News report. These types of changes to trial plans are routine.
Source Fool.com
